caa a22 4500 397592434 CHVBK 20180308164942.0 cr unu---uuuuu 161202e199605 xx s 000 0 eng 10.1093/jac/37.suppl_A.123 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_A.123 A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men [Elektronische Daten] [I. Phillips, C. Dimian, D. Barlow, H. Moi, E. Stolz, W. Weidner, E. Perea] A multicentre, double-blind, randomised study comparing the efficacy and safety of oral sparfloxacin (200 mg on day 1 followed by 100 mg daily for 2 or 6 additional days) with doxycycline (200 mg once daily for 7 days) in the treatment of non-gonococcal urethritis in men was conducted. The overall success rates for the three treatment groups were statistically equivalent both at the end of treatment and at the follow-up visits. For chlamydial urethritis, the rates of relapse or possible reinfection were similar in the 7-day sparfloxacin and doxycycline groups. For ureaplasmal urethritis and urethritis of unknown aetiology, the rates of relapse or possible reinfection were lower in the 7-day sparfloxacin group than in the other two treatment groups. Sparfloxacin was well tolerated. A 7-day sparfloxacin regimen appears to be a useful alternative to doxycycline for the treatment of non-gonococcal urethritis in men. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Phillips I. Department of Microbiology Spain aut Dimian C. Department of Genito-Urinary Medicine St Thomas' Hospital, London SE1 7EH, UK aut Barlow D. Department of Genito-Urinary Medicine St Thomas' Hospital, London SE1 7EH, UK aut Moi H. Department for STD and HIV Gronland PK, N-0133, Oslo, Norway aut Stolz E. Dermatologie an Venerologie Academisch ziekenhuis 3015GD, Rotterdam, The Netherlands aut Weidner W. Zentr. Chirurgie Abt. Urologie, Georg August Universitat 3400 Gottingen, Germany aut Perea E. Catedratico de Microbiologia de la Facultad de Medicina, Universidad de Sevilla E-41009, Seville, Spain aut Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-05), 123-134 0305-7453 37<123 1996 37 jac https://doi.org/10.1093/jac/37.suppl_A.123 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_A.123 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Phillips I. Department of Microbiology Spain aut NATIONALLICENCE 700 1- Dimian C. Department of Genito-Urinary Medicine St Thomas' Hospital, London SE1 7EH, UK aut NATIONALLICENCE 700 1- Barlow D. Department of Genito-Urinary Medicine St Thomas' Hospital, London SE1 7EH, UK aut NATIONALLICENCE 700 1- Moi H. Department for STD and HIV Gronland PK, N-0133, Oslo, Norway aut NATIONALLICENCE 700 1- Stolz E. Dermatologie an Venerologie Academisch ziekenhuis 3015GD, Rotterdam, The Netherlands aut NATIONALLICENCE 700 1- Weidner W. Zentr. Chirurgie Abt. Urologie, Georg August Universitat 3400 Gottingen, Germany aut NATIONALLICENCE 700 1- Perea E. Catedratico de Microbiologia de la Facultad de Medicina, Universidad de Sevilla E-41009, Seville, Spain aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-05), 123-134 0305-7453 37<123 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford